Reports & Insights | Pharma Contract Manufacturing

The pharmaceutical industry is undergoing a rapid transformation, with Contract Manufacturing Organisations (CMOs) and Contract Development and Manufacturing Organisations (CDMOs) playing an increasingly vital role. Ahead of the Pharma Contract Manufacturing Summit 2025, Pharma IQ has put together a comprehensive market report, that delves into the trends, challenges, and opportunities shaping the future of pharmaceutical manufacturing.

Why Download This Report? This resource provides actionable insights for industry professionals navigating the complexities of pharmaceutical manufacturing. From building resilient supply chains to achieving sustainability goals, the report serves as a roadmap for optimising partnerships, operations, and compliance.

Download the report now to explore how you can stay ahead in a rapidly evolving market. Key takeaways include: 

• Market Insights: Learn how the global CMO/CDMO market is projected to reach $310.9 billion by 2030, driven by demand for outsourcing and innovative drugs.
• Digital Transformation: Discover how AI, IoT, and smart manufacturing are revolutionising operational efficiency and regulatory compliance.
• Sustainability: Explore how green chemistry, carbon neutrality, and sustainable packaging are redefining industry standards.
• Geopolitical Complexities: Understand how regulations like the BIOSECURE Act and regional strategies are reshaping supply chain resilience.
• Innovation: Learn about the role of additive manufacturing, predictive analytics, and lights-out manufacturing in driving future growth.

This exclusive interview with Philip Coetzee, Director of CMO Management at Daiichi Sankyo, provides a strategic look at the contract manufacturing landscape ahead of the Pharma Contract Manufacturing Summit 2025. 

In an exclusive interview ahead of the Pharma Contract Manufacturing 2025 Summit, Marta Ferrer, External Supply Quality Assurance Manager at Sandoz, shares invaluable insights into the evolving dynamics of pharmaceutical manufacturing partnerships. With the increasing complexity of global supply chains and heightened regulatory demands, the importance of quality assurance has never been greater.

This insightful interview with Sam Badawy, Quality Assurance Manager at Bayer, offers a comprehensive look at the challenges and strategies in maintaining quality assurance within pharma contract manufacturing. As regulatory landscapes shift and digital transformation accelerates, Sam Badawy discusses key strategies for building resilient CMO partnerships.

This exclusive interview with Dr. Ulrich Rümenapp, Senior Biotech Program Lead at Bayer AG, delves into the key strategies for biotech manufacturing success.

For pharma professionals involved in biotech manufacturing, this interview offers actionable insights on balancing quality, cost, and control. Gain expert perspectives on how to leverage specialised partnerships, maintain compliance, and navigate the complexities of biotech production for future-ready manufacturing strategies.

Explore effective strategies for successful CMO partnerships in pharma. Ahead of the upcoming Pharma Contract Manufacturing Summit, 26-27 March 2025, Pharma IQ spoke to Maik Talarczyk, Head PMO ESO at Sandoz, to discuss quality alignment, innovation, and future-proofing contract manufacturing partnerships in this exclusive interview.

Ahead of the Pharma Contract Manufacturing 2025 Summit, discover expert insights from speakers Kyriakos Kansos and George Ntortas of Fuliginous Management Consulting, on building effective pricing models for CDMO partnerships. This exclusive interview Pharma IQ explores key strategies for navigating pricing complexities, leveraging value-based approaches, and crafting risk-sharing agreements that drive profitability and strengthen collaborations. Download this exclusive content to gain expert advice on creating resilient and profitable pricing strategies for the CDMO market.

The Pharma Contract Manufacturing 2025 conference will focus on fostering sustainable practices in pharmaceutical manufacturing. This presentation from Philip Coetzee, Director CMO Management, Daiichi Sankyo, delivered at the PCM 2024 event, highlights innovative sustainability strategies within pharmaceutical manufacturing. Drawing from his extensive experience, Philip discusses critical milestones in implementing renewable energy, enhancing energy efficiency, and meeting global environmental standards. Gain valuable insights into actionable steps your organisation can take to drive sustainability goals while maintaining operational excellence.

The Pharma Contract Manufacturing 2025 conference is dedicated to addressing the most critical challenges in the pharmaceutical manufacturing landscape, with a focus on fostering strong partnerships and operational excellence. This exclusive presentation from Pharma Contract Manufacturing 2024 explores key negotiation strategies tailored for the pharma industry, equipping professionals with the tools to enhance their contract manufacturing operations.

Join us at our free virtual panel ahead of our Annual Pharma Contract Manufacturing Conference. The panel will feature five distinguished industry experts, each bringing unique perspectives and deep expertise in their respective fields.

Together, they will explore emerging trends, challenges, and predictions for 2025, covering topics such as advancements in manufacturing technologies, regulatory shifts, supply chain strategies, and sustainability initiatives. You will gain actionable insights into how these developments could impact the industry landscape and your own operations.

The Pharma Contract Manufacturing 2025 conference will focus on fostering long-term, sustainable partnerships in the pharmaceutical manufacturing space. This presentation from 2024 provides key insights into harmonising processes, values, and goals between CMOs and their partners, addressing critical issues such as regulatory compliance, sustainability, and cost management.

The importance of selecting the right CMO/CDMO partnership is critical, as the benefits go beyond significant cost reduction, there is also the potential to improve and develop more strategies for pharmaceutical companies. But only if a mutually collaborative, open and trusting relationship is built.

Ahead of the Pharma Contract Manufacturing Summit 2025, we spoke exclusively to Federica Fraschetti, Associate Director, Focus Factory Leader – Bio ExM, MSD about the key do’s and don’ts when selecting a CMO, to help you find the right fit for your pharmaceutical company.

Download the full article here >>>

When selecting partners, meeting stringent sustainability criteria along entire pharmaceutical supply chains has far-reaching environmental, economic and reputational benefits. Whilst adding a sustainability criteria to the bidding process is a positive one for driving more responsible operations across the entire pharmaceutical industry, it simultaneously amplifies the complexity of selecting a Contract Manufacturing Organization (CMO).

Unlock the report to delve into vital statistics and expert insights, covering:

• Stringent selection criteria: understand the pivotal role stringent criteria play in shaping responsible and sustainable partnerships
• Bottom line benefits: explore the tangible economic advantages that sustainable practices bring to the forefront of your pharmaceutical operations
• Technology for greener supply chains: navigate the latest innovations driving sustainability in pharmaceutical supply chains and stay ahead in the industry

Topped up with expert commentary from industry leaders: Philip Coetzee, Director CMO Management, Daiichi Sankyo and Gregory Vanderwinden, Associate Director – External Manufacturing EU, MSD.

Elevate your CMO selection process and lead the way towards a greener, more sustainable pharmaceutical future.  Access the report now.

Ahead of the Pharma Contract Manufacturing Summit 2023, Pharma IQ spoke exclusively to David Berry, Head of Digital Business Systems - Pharma, CPI about connecting automation to a QP dashboard at the MMIC, to help you discover new opportunities and solutions to your current pharma manufacturing challenges. 

Fill in the form below to access David's exclusive insights >>>

Pharma IQ surveyed over 50 industry professionals, and accompanied by commentary from Ulrich Ruemenapp, Head of Launch Preparation at Bayer, this report will take an in-depth look at the most important components when selecting a CMO, the greatest risks when choosing to outsource and best practises for managing CMO networks.

Download the full report now >>>

Additional benefits to downloading the full report:

• Discover where the industry is at in its Pharma outsourcing journey
• The important factors to consider when selecting a CMO
• Find out more about how to reduce your external partner footprint
• Industry results for the greatest risks of outsourcing 
• Learn more about the characteristics that are most valued in a CMO
• Professional opinions on what areas are missing from the CMO market

As pharmaceutical businesses worldwide become more aware of the importance of meeting sustainability goals, it is inevitable that this will become a consideration when selecting a contract manufacturing organisation (CMO) or contract development and manufacturing organisation (CDMO). But it’s important to ensure that meeting sustainability goals when collaborating with external partners is genuine rather than just greenwashing.

That's why ahead of Pharma Contract Manufacturing 2024 we have collated exclusive insights on CMO Selection - Making Sustainability a Top Priority.

Access the infographic and dive into:

• The Top 5 considerations for sustainable CMO selection
• Key questions for the selection process
• Changing the culture strategy
• Examining your Scope 3 emissions
• Real-world examples of setting measurable targets
• Looking ahead: The big picture benefits

Due to the pandemic, the medical needs of populations worldwide are increasing and there is a huge demand for pharmaceutical products, causing CMOs and CDMOs to be increasingly sought after by pharmaceutical companies for their specialist equipment, facilities, labour force and cost-effective production. However, as large pharmaceutical companies start to develop in-house manufacturing capabilities, there is more and more competition between CMOs and CDMOs to prove they are the best partner.

Ahead of this year's Pharma Contract Manufacturing 2022 event, we spoke to Ulrich Rümenapp, Head of Launch Preparation and Coordination at Bayer AG, about the importance of maintaining positive partnerships with CMOs and CDMOs, to help you create and maintain positive partnerships with your CMOs and CDMOs, and build industry resilience.

Download the full interview now >>

Additional benefits to downloading the full interview:

• Discover how the last 18 months has impacted CMO and/or CDMO partnerships
• Learn about the greatest challenges of complex product manufacturing, and the top tips for overcoming these challenges
• Find out more about the benefits and opportunities of CMO and/or CDMO partnerships
• A summary of the key initiatives for maintaining positive CMO and/or CDMO partnerships over the next 2 years

It’s hardly surprising that pharma companies are changing the way they work with external partners, with increasing pressures on quality, cost and scalability determining not only which manufacturers the industry outsources to, but how many partners to take on.

With this in mind, Pharma IQ spoke with Simon Hendry, BD Director, Adare Pharmaceuticals, on the current challenges and best practices of streamlining external networks of CMOs. Hendry, speaks in-depth on the critical success factors you need to uncover in the selection process and how to manage emerging markets, all whilst ensuring quality isn’t compromised.

Download the full interview on the right >>

Other key benefits to downloading the full interview:

• Analysing what changes need to be made over the next 12-24 months to meet the main challenges of the industry
• Understanding the best practices for building a successful CMO partnership
• Exploring what criteria is most valuable to the industry when selecting a CDMO
  

Interested in seeing who you will meet at Pharma Contract Manufacturing 2025? Download our 2025 attendee list to see who is joining us so far! At the event, we will bring industry leaders, experts, and innovators together from the CMO/CDMO and pharmaceutical industry, to engage in meaningful discussions and share best practices to tackle the challenges of today.

Present your boss with this customizable letter detailing the reasons why you should attend Pharma Contract Manufacturing 2025 from 26th - 27th March 2025, in Berlin, Germany. Just download the letter template below, adjust as necessary (or edit as needed) and submit! We hope to welcome you there!